Modafinil Aurobindo (Modafinil)

Modafinil acts on central nervous system pathways that regulate wakefulness, making it useful for several sleep‑related disorders.

• Narcolepsy: reduces excessive daytime sleepiness and improves alertness in patients with narcolepsy.
• Obstructive sleep apnea: alleviates residual daytime sleepiness when used alongside standard apnea therapy.
• Shift work disorder: helps workers maintain alertness during atypical work hours.

• Modafinil promotes wakefulness primarily by inhibiting dopamine reuptake, thereby increasing extracellular dopamine levels in key brain regions. It also modulates orexin/hypocretin pathways and influences histamine and norepinephrine activity, collectively enhancing cortical arousal without producing the classic stimulant‑type sympathomimetic effects.

Modafinil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate pain often reported during early treatment.
• Nausea: transient gastrointestinal discomfort.
• Insomnia: difficulty falling or staying asleep when taken later in the day.
• Anxiety: heightened nervousness or restlessness.
• Dry mouth: reduced salivation.
• Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Psychiatric events: including hallucinations, mania, or severe depression.
• Cardiovascular complications: hypertension, arrhythmia, or chest pain.
• Hypersensitivity: anaphylaxis or angioedema.
• Hepatic injury: elevated liver enzymes or hepatitis.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor for adverse events.

• Cardiovascular assessment: check blood pressure and cardiac history.
• Hypersensitivity screening: avoid in patients with known allergy to modafinil.
• Psychiatric monitoring: watch for new or worsening mental health symptoms.
• Hepatic function: use caution and consider dose adjustment in liver impairment.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Modafinil can affect the metabolism of several co‑administered drugs, requiring attention to potential interactions.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce modafinil exposure.
• Hormonal contraceptives: modafinil can lower contraceptive effectiveness, increasing pregnancy risk.
• Monoamine oxidase inhibitors: concurrent use may precipitate hypertensive crises.

Moderate Interactions (Monitor Closely)

• Caffeine and other stimulants: may amplify central nervous system stimulation.
• Selective serotonin reuptake inhibitors: increased risk of insomnia or anxiety.
• Antihypertensive agents: possible reduction in blood‑pressure‑lowering effect.